{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06109779",
            "orgStudyIdInfo": {
                "id": "D7025C00001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506054-20-00",
                    "type": "OTHER",
                    "domain": "EU Clinical Trial Number"
                }
            ],
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)",
            "officialTitle": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)"
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.",
            "detailedDescription": "This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent."
        },
        "conditionsModule": {
            "conditions": [
                "Biliary Tract Cancer"
            ],
            "keywords": [
                "Adenocarcinoma of the biliary tract",
                "Biliary tract Cancer",
                "Gall bladder cancer",
                "Intrahepatic Cholangiocarcinoma",
                "Distal Cholangiocarcinoma",
                "Perihilar Cholangiocarcinoma",
                "Klatskin Tumors",
                "Bile duct cancer",
                "Immunotherapy",
                "Cholangiocarcinoma",
                "Rilvegostomig",
                "S-1",
                "Gemcitabine/cisplatin",
                "Capecitabine"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Double-blind masking",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 750,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)",
                    "interventionNames": [
                        "Drug: Rilvegostomig",
                        "Drug: Capecitabine",
                        "Drug: Gemcitabine/Cisplatin",
                        "Drug: S-1 [Tegafur/Oteracil/gimeracil]"
                    ]
                },
                {
                    "label": "Arm B",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Capecitabine",
                        "Drug: Gemcitabine/Cisplatin",
                        "Drug: S-1 [Tegafur/Oteracil/gimeracil]"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Rilvegostomig",
                    "description": "Rilvegostomig IV (intravenous) Q3W",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo IV (intravenous) Q3W",
                    "armGroupLabels": [
                        "Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine/Cisplatin",
                    "description": "Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "S-1 [Tegafur/Oteracil/gimeracil]",
                    "description": "S-1 \\[Tegafur/Oteracil/gimeracil\\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1)\n* Provision of a tumor sample collected at surgical resection.\n* Randomization within 12 weeks after resection with adequate healing and removal of drains.\n* Confirmed to be disease-free by imaging within 28 days prior to randomization.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n\nExclusion Criteria:\n\n* Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis.\n* Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors.\n* Any anti-cancer therapy for BTC prior to surgery\n* Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease\n* Current or prior use of immunosuppressive medication within 14 days before the first dose\n* Thromboembolic event within 3 months\n* Active HBV or HCV infection unless treated.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ]
        }
    },
    "hasResults": false
}